Olanib 150 (Olaparib)

Basic Product Information of Olanib 150 (Olaparib) 150mg

How Olanib 150 (Olaparib) Works

Olanib 150 contains Olaparib, a potent oral inhibitor of the Poly (ADP-ribose) Polymerase (PARP1, PARP2 and PARP3) family of enzymes. PARP enzymes play an essential role in repairing single-strand breaks (SSBs) in DNA. When these breaks are not repaired, they progress to double-strand breaks (DSBs) during cell replication, which healthy cells normally correct through homologous recombination repair (HRR).

In tumours carrying BRCA1/BRCA2 mutations or other homologous recombination deficiencies (HRD), this repair pathway is impaired. Olaparib works by inhibiting PARP enzymatic activity and trapping PARP-DNA complexes, preventing single-strand break repair. In HRD tumour cells, the resulting accumulation of unrepaired DNA damage becomes lethal, a mechanism known as synthetic lethality, leading to selective destruction of cancer cells while sparing healthy tissue to a greater extent.

Olanib 150 is administered as a convenient oral tablet, offering an alternative to intravenous chemotherapy for maintenance and targeted treatment in patients whose tumours carry the relevant genetic biomarkers. Treatment eligibility is typically confirmed through BRCA or HRD biomarker testing prior to initiation.

Indications for Olanib 150 (Olaparib)

Olanib 150 (Olaparib) is indicated for the following conditions:

Benefits of Olanib 150 (Olaparib) 150mg

How to Take Olanib 150 (Olaparib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Olanib treatment. Your oncologist will check complete blood counts at baseline and monthly thereafter to monitor for anaemia, neutropenia, and thrombocytopenia, and will watch for early signs of myelodysplastic syndrome or acute myeloid leukaemia. Monitoring also includes assessment for pneumonitis (new or worsening respiratory symptoms), venous thromboembolism, and periodic review of renal function. Treatment may be interrupted or dose-reduced to manage adverse reactions such as nausea, vomiting, diarrhoea, or anaemia. Report any unusual bruising, bleeding, persistent fatigue, breathlessness, or fever to your doctor immediately.

Drug Interactions and Important Information

Avoid concomitant use of Olanib with strong or moderate CYP3A4 inhibitors (such as itraconazole, clarithromycin, and certain protease inhibitors) or strong or moderate CYP3A4 inducers (such as rifampicin, carbamazepine, and phenytoin) where possible, as these significantly alter Olaparib plasma exposure. If co-administration cannot be avoided, dose adjustment as directed by the prescribing physician is required.

Use with caution alongside other myelosuppressive anticancer agents, as combined use may potentiate and prolong bone marrow suppression. Women of childbearing potential should use effective, non-hormonal contraception during treatment and for at least one month after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Olanib.

Side Effects and Precautions

Who Should Use Olanib 150 (Olaparib)?

Olanib is suitable for adult patients with BRCA-mutated or HRD-positive ovarian, fallopian tube, or primary peritoneal cancer, HER2-negative BRCA-mutated breast cancer, germline BRCA-mutated metastatic pancreatic cancer, or HRR gene-mutated metastatic castration-resistant prostate cancer, as confirmed by an approved biomarker or genetic test. It is prescribed by medical oncologists and gynaecologic oncologists experienced in genomically-guided cancer therapy. A thorough medical assessment including BRCA/HRR testing, baseline blood counts, and renal and hepatic function is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, hematology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Olanib under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Olanib is one of Everest’s specialty oncology products, offering a bioequivalent alternative to Lynparza by AstraZeneca at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Olanib 150 (Olaparib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Olanib 150 (Olaparib) from Mediaid Pharmacy?

Olanib 150 represents an important, targeted option in the treatment of BRCA-mutated and HRD-positive cancers. As the generic equivalent of Lynparza by AstraZeneca, it delivers the same active ingredient, Olaparib, with the same proven PARP-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Olanib 150 gives patients and oncology centres worldwide access to precision cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Olaparib option with worldwide delivery, Olanib 150 from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Olanib 150 (Olaparib)